Why biomarker results come before any targeted therapy discussion
A targeted cancer drug is not chosen because a tumour has a particular name or location. It is considered because the tumour carries a molecular feature the drug is designed to act on. That is the core reason biomarker results sit at the start of the conversation, not at the end. Without a clear biomarker report, a clinician cannot judge whether a particular targeted option is relevant to your case at all.
This matters for an overseas enquiry because the first useful step is not choosing a hospital or asking about a drug by name. It is establishing what has already been tested, what the result was, and whether the report can be read by the treating team. A pathology summary that says only 'adenocarcinoma' or 'lung cancer' does not answer the molecular question. The actual test report, with the gene or protein assessed and the result, is what a clinician needs to see.
It also matters because a biomarker finding does not automatically mean a treatment is available, suitable or funded for you. It is one input into a clinical assessment. The treating hospital decides whether a targeted approach is appropriate, what alternatives exist, and how any treatment would be monitored. Your role before that decision is to make the molecular picture as clear as possible.
What a biomarker report actually contains, and what to send
Biomarker testing looks for specific molecular features in tumour tissue or, in some situations, in blood. The report usually names the gene, protein or marker tested, the method used, and the result. Some reports also note the proportion of cells showing a feature or a measure of how much signal was detected. These details can change how a clinician interprets the finding, so a one-line summary is often not enough.
For an initial review, the most useful documents are the full molecular or genomic test report, the original pathology report, imaging reports that show where the disease is, and a current treatment summary. The treatment summary should list drugs already used, when they were used, and what happened. Previous targeted drugs are especially relevant because prior exposure can affect how a clinician thinks about the next option.
If the biomarker test was done some time ago, or if no molecular testing has been done, say so plainly rather than guessing. The treating centre can then tell you whether existing material can be re-tested or whether further assessment is needed. Do not arrange new tests on your own before a clinician has reviewed what you already have; the right test depends on the tumour type, the prior results and the clinical question.
A practical way to organise this is to prepare a short index page listing each report, the date, the hospital that issued it and the language. Then attach the reports in the same order. This is not a substitute for the clinical review, but it reduces the chance that a key result is missed.
The specific drug and biomarker context the centre must confirm
When you contact a centre about targeted therapy, the useful question is not 'do you offer targeted therapy'. It is whether the centre can assess your case against the specific biomarker result and the specific drug context. That means naming the biomarker, the result, and any targeted drug you have already received or are currently receiving.
There are several things only the treating team can confirm. First, whether the biomarker finding is actionable in your tumour type. Second, whether a relevant drug is appropriate given your prior treatments, current condition and other medicines. Third, whether that drug is available through the hospital you are asking about. Fourth, how treatment and monitoring would continue if you travelled. None of these can be settled by an article or a general enquiry.
It also helps to ask how the centre handles an ongoing treatment. If you are already on a targeted drug, the question is whether and how it could be continued, adjusted or monitored during a stay in China. If you are between treatments, the question is what assessment is needed before a new option is considered. These are different situations and they lead to different preparation.
Write the drug name exactly as it appears on your prescription or treatment record, including the dose and schedule if you know them. A brand name alone can be ambiguous across countries. The generic name plus the biomarker result gives the clinical team the clearest starting point.
Why a records-based review is not the same as treatment approval
A records-based opinion can help you understand whether your biomarker profile and treatment history are relevant to the options a centre might consider. It can also identify what information is missing. It does not, however, establish that you are eligible for a particular drug, that the hospital will accept your case, or that a treatment plan is already agreed.
This distinction matters when you are deciding whether to travel. A review of records is a step in the assessment process. Final suitability, prescriptions and treatment decisions belong to the treating hospital and its licensed clinicians after they have assessed you. If a centre offers a remote opinion, ask what it can and cannot conclude from your documents, and what would still need to be confirmed in person.
It is also reasonable to ask how the centre would handle uncertainty. If a biomarker result is borderline, if the test method differs from what the centre uses, or if the original material is no longer available, the clinical team should explain what that means for your case. A clear answer to that question is more useful than a general assurance.
Keep the enquiry focused on your actual situation. A short summary of the diagnosis, the biomarker result, the drugs already used and your main question gives the team enough to identify the relevant next step. You do not need to send a complete medical archive at first contact.
Questions to ask before you plan any travel
Once you know the biomarker context, the next decision is whether an assessment in China is worth pursuing and what it would involve. The answers depend on the centre, so these are questions to put in writing rather than assumptions to make.
Ask whether the centre can review your specific biomarker report and prior treatment history, and what additional documents it needs. Ask whether the relevant drug is available through that hospital and how availability is confirmed. Ask how ongoing treatment and monitoring would be arranged if you travelled, and what would happen if the drug were not suitable. Ask what the written estimate for assessment and treatment would include, and which parts are hospital charges rather than coordination fees.
It is also worth asking how the centre would communicate with your current treating team, if that is something you want. Continuity of care matters when a targeted drug is already part of your treatment. The receiving clinicians make their own judgement, but they can do so more reliably when they have your records and a clear picture of what has already been tried.
Do not delay necessary local care while an overseas enquiry is in progress. If your condition changes or symptoms worsen, local assessment takes priority. An overseas review is a planning step, not a reason to postpone urgent treatment.
- Confirm whether the centre can assess your specific biomarker result and prior drugs.
- Ask what additional records or re-testing it would need, and who decides that.
- Ask how availability of a relevant drug would be confirmed for your case.
- Ask how ongoing treatment and monitoring would continue during and after a stay.
- Ask what a written estimate covers and which charges are hospital fees.
- Ask how the centre would share information with your current treating team.
A practical next step for your enquiry
Start with a short summary rather than a full archive. Include the diagnosis, the biomarker test and result, the targeted drugs already used, your current treatment status and your main question. That is enough for an initial review to identify what is missing and which next step is relevant.
An initial enquiry is free and does not commit you to a proxy consultation or any treatment. If a records-based opinion would help, that can be discussed separately. The hospital decides suitability, and any treatment plan is confirmed only after the clinical team has assessed your case.
If you would like to begin, send the summary through the enquiry form, by email or by WhatsApp. Further records can be shared after first contact, once the team has told you what is actually needed for your situation.
Sources & scope of this guide
References and official service information relevant to this guide.
This is general planning information and has not been individually reviewed by a doctor. Medical decisions and personal treatment advice come from your treating clinicians.